Interim IIT Data Explore Sculptra, Restylane for Menopause, Weight Loss–Related Aesthetic Changes

Interim findings from 2 ongoing investigator-initiated trials supported by Galderma suggest potential roles for Sculptra and the Restylane portfolio in treating aesthetic changes associated with menopause and medication-driven weight loss.

In one interim analysis led by Sabrina Fabi, MD, 20 female patients with mild to moderate abdominal skin laxity were evaluated to characterize tissue changes associated with prescription weight loss medications. According to the company, investigators found a statistically significant 4-fold reduction in adipose-derived stem cells compared with patients not taking these medications, while fibroblast levels were preserved. The findings were presented as a possible biologic explanation for the volume-related changes clinicians are increasingly observing after medication-driven weight loss.

A second interim investigator-initiated trial, led by Andreas Nikolis, MD, examined treatment sequencing in menopausal women over 9 months on the face and décolletage. Galderma reported that both sequences, combining Restylane Skinboosters and Sculptra, were associated with progressive improvements in facial hydration, skin-barrier measures, and patient-reported satisfaction. The company said the most pronounced hydration gains were seen when Restylane Skinboosters were used first.

These findings remain interim and should be interpreted cautiously until full study methods and peer-reviewed results are available. Several efficacy and mechanism statements in the source material, including references to regenerative effects across skin layers and optimal sequencing, would benefit from confirmation in complete published datasets. Still, the early readout reflects growing industry interest in how aesthetic treatment plans may be adapted for patients experiencing skin and soft-tissue changes during menopause or after medication-driven weight loss.